ClinicalTrials.gov
public full text
Public Domain
AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19
The study is an unblinded, randomized, controlled trial for use of the AirFlO2 device for patients admitted to Duke Hospital with COVID-19 and tachypnea (RR \>20 breaths/min) and/or hypoxia (Oxygen saturation \<94% on room air or requiring supplemental oxygen at baseline).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Mask Hypoxia in Subjects Using Masks to Prevent Infection Spread#876336
- Role of HVNI in Severe Chest Trauma#978858
- Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With CF#889935
- Conservative Versus Conventional Oxygen Administration in Critically Ill Patients#1214809
- Normal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU)#1112975
Record · ID 1372882
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive